123 related articles for article (PubMed ID: 11401182)
1. Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases.
Gandhi SK; Arguelles L; Boyer JG
Pharmacotherapy; 2001 Jun; 21(6):684-90. PubMed ID: 11401182
[TBL] [Abstract][Full Text] [Related]
2. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
3. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States.
Pathak R; Giri S; Aryal MR; Karmacharya P; Bhatt VR; Martin MG
Support Care Cancer; 2015 Mar; 23(3):615-7. PubMed ID: 25556610
[TBL] [Abstract][Full Text] [Related]
4. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.
Tai E; Guy GP; Dunbar A; Richardson LC
J Oncol Pract; 2017 Jun; 13(6):e552-e561. PubMed ID: 28437150
[TBL] [Abstract][Full Text] [Related]
5. Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy.
Chrischilles EA; Klepser DG; Brooks JM; Voelker MD; Chen-Hardee SS; Scott SD; Link BK; Delgado DJ
Pharmacotherapy; 2005 May; 25(5):668-75. PubMed ID: 15899728
[TBL] [Abstract][Full Text] [Related]
6. The economic impact of acute coronary syndrome on length of stay: an analysis using the Healthcare Cost and Utilization Project (HCUP) databases.
LaMori JC; Shoheiber O; Dudash K; Crivera C; Mody SH
J Med Econ; 2014 Mar; 17(3):191-7. PubMed ID: 24451040
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre.
Schelenz S; Giles D; Abdallah S
Ann Oncol; 2012 Jul; 23(7):1889-93. PubMed ID: 22048152
[TBL] [Abstract][Full Text] [Related]
8. Modeling administrative outcomes in fever and neutropenia: clinical variables significantly influence length of stay and hospital charges.
Rosenman M; Madsen K; Hui S; Breitfeld PP
J Pediatr Hematol Oncol; 2002 May; 24(4):263-8. PubMed ID: 11972093
[TBL] [Abstract][Full Text] [Related]
9. National Trends in Hospitalization for Fever and Neutropenia in Children with Cancer, 2007-2014.
Lekshminarayanan A; Bhatt P; Linga VG; Chaudhari R; Zhu B; Dave M; Donda K; Savani S; Patel SV; Billimoria ZC; Bhaskaran S; Zaid-Kaylani S; Dapaah-Siakwan F; Bhatt NS
J Pediatr; 2018 Nov; 202():231-237.e3. PubMed ID: 30029861
[TBL] [Abstract][Full Text] [Related]
10. The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset.
Lingaratnam S; Thursky KA; Slavin MA; Kirsa SW; Bennett CA; Worth LJ
Intern Med J; 2011 Jan; 41(1b):121-9. PubMed ID: 21272176
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.
Dulisse B; Li X; Gayle JA; Barron RL; Ernst FR; Rothman KJ; Legg JC; Kaye JA
J Med Econ; 2013; 16(6):720-35. PubMed ID: 23452298
[TBL] [Abstract][Full Text] [Related]
12. Effect of weekend compared with weekday stroke admission on thrombolytic use, in-hospital mortality, discharge disposition, hospital charges, and length of stay in the Nationwide Inpatient Sample Database, 2002 to 2007.
Hoh BL; Chi YY; Waters MF; Mocco J; Barker FG
Stroke; 2010 Oct; 41(10):2323-8. PubMed ID: 20724715
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
Bennett CL; Calhoun EA
Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
[TBL] [Abstract][Full Text] [Related]
14. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
[TBL] [Abstract][Full Text] [Related]
15. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
[TBL] [Abstract][Full Text] [Related]
16. Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.
Jacobs VR; Mayer SC; Paessens BJ; Bernard R; Harbeck N; Kiechle M; Ihbe-Heffinger A
Onkologie; 2011; 34(11):614-8. PubMed ID: 22104158
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic burden of emergency department presentations for neutropenia following outpatient chemotherapy for cancer in Victoria, Australia.
Livingston PM; Craike M; Slavin M
Oncologist; 2012; 17(7):998-1004. PubMed ID: 22707511
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilization and costs associated with gastroparesis.
Wadhwa V; Mehta D; Jobanputra Y; Lopez R; Thota PN; Sanaka MR
World J Gastroenterol; 2017 Jun; 23(24):4428-4436. PubMed ID: 28706426
[TBL] [Abstract][Full Text] [Related]
19. The economic burden of neonatal abstinence syndrome in the United States.
Corr TE; Hollenbeak CS
Addiction; 2017 Sep; 112(9):1590-1599. PubMed ID: 28612362
[TBL] [Abstract][Full Text] [Related]
20. Fever and neutropenia hospital discharges in children with cancer: A 2012 update.
Mueller EL; Croop J; Carroll AE
Pediatr Hematol Oncol; 2016 Feb; 33(1):39-48. PubMed ID: 26900730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
